EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results EL CAJON, Calif. - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2026. Summary of Results of Operations - Third Quarter Net product sales were $506,000 and $489,000 for the fiscal third quarters ended April 30, 2026 and 2025, respectively. The $17,000 increase was attributable to higher sales across our distribution network. Net loss for the fiscal third quarter ended April 30, 2026 was $624,000, compared to $580,000 for the fiscal third quarter ended April 30, 2025. Net loss, excluding share-based compensation, for the fiscal third quarter ended April 30, 2026 was $569,000, compared to $547,000 for the fiscal third quarter ended April 30, 2025. Net loss per share was ($0.01) for the fiscal third quarters ended April 30, 2026 and 2025, respectively. Summary of Results of Operations - Prior Nine Months Net product sales were $1,656,000 and $1,435,000 for…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
PURE Bioscience, Inc.
PUREOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On June 15, 2026, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal third quarter ended April 30, 2026 and related information. A copy of the press release is attached as Exhibit 99.1.…
Recent company filings
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operations and Financial Condition.
On
June 15, 2026, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal third
quarter ended April 30, 2026 and related information. A copy of the press release is attached as Exhibit 99.1.
The
information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated
by reference into any registration statement or other document filed with the Securities and Exchange Commission.